Clinical outcomes following switch from risankizumab to guselkumab in Crohn&apos;s disease: a real-world case series

Inflammatory Bowel Disease

Establishing a Multiple Outcome Set for Crohn's Disease in Real-World Evidence Studies: Results from a Delphi e-Survey

J Crohns Colitis

Moreira PL, Dignass A, Estevinho MM, Santiago M, Reinisch W, Sands BE, D'Haens G, Mantzaris GJ, Danese S, Peyrin-Biroulet L, Dotan I, Jairath V, Magro F, International Organization for the Study of Inflammatory Bowel Diseases (IOIBD)

doi: 10.1093/ecco-jcc/jjaf178

Inflammatory Bowel Disease

Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: the USBIOS IG-IBD Study

Clin Gastroenterol Hepatol

Ribaldone DG, Tribocco E, Scaldaferri F, Murgiano M, Parello S, Di Vincenzo F, Del Gaudio A, Puca P, Napolitano D, Papa A, Lopetuso LR, Laterza L, Bezzio C, Armuzzi A, Farinola V, Savarino EV, Zingone F, Barberio B, Bertin L, Todeschini A, Variola A, Carvalhas Gabrielli AM, Ferretti F, Cannatelli R, Gravina AG, Pellegrino R, Viola A, De Francesco C, Bossa F, Pastorelli L, Felice C, Dragoni G, Canova D, Cingolani L, Spagnuolo R, Terpin MM, Zilli A, Magiotta A, Segatta F, Saibeni S, Juverdeanu A, Vernero M, Caviglia GP

doi: 10.1016/j.cgh.2026.08.014

Inflammatory Bowel Disease

Clinical Outcome After Entero-Enteric Anastomosis for Crohn's Disease: A Case-Control Study

J Crohns Colitis

Neri B, Schiavone SC, Mancone R, Fiorillo M, Fonsi A, Calabrese E, Perugini L, Piccione G, Di Matteo FM, Marafini I, Lolli E, Sica GS, Monteleone G, Biancone L

doi: 10.1093/ecco-jcc/jjaf163

Inflammatory Bowel Disease

Real-World Effectiveness of Upadacitinib for Perianal Crohn's Disease: A Multi-Center Retrospective Study

Clin Gastroenterol Hepatol

Devi J, Patel A, Quraishi B, Dev B, Tan T, Kline M, Chowla N, Ramesh PR, Ballard DH, Huang L, Jaiprada F, Samaan S, Stone M, Khan A, Seeraj AA, Alanazi S, Xu A, Maas L, Jajoo A, Parian A, Altinmakas E, Ehman EC, Davenport MS, Li S, Chithriki M, Shukla R, McCurdy J, Yarur AJ, Bishu S, Johnson AM, Benjamin M, Dulaney D, Serre-Yu W, Deepak P

doi: 10.1016/j.cgh.2026.05.003

Inflammatory Bowel Disease

Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry

United European Gastroenterol J

Iborra M, Botella B, Martín-Arranz MD, Ceballos D, Martínez-Pascual C, Garrido A, Varela P, Moreta M, Brunet-Mas E, González-Lama Y, Rodríguez-González E, Vicuña M, Gisbert JP, Ordás I, Argüelles-Arias F, Tosca-Cuquerella J, Vicente-Lidón R, Sierra-Ausín M, Rodríguez-Lago I, Martín-Rodríguez D, Paredes JM, Sicilia B, García de la Filia I, Jiménez N, Barreiro-de Acosta M, Betoré E, Ferrer-Bradley I, García-Alles L, Huguet JM, Castellet-Farrús S, García MJ, Gutiérrez-Casbas A, Ponferrada-Díaz Á, Ramos L, Calafat M, Vera I, Suárez-Ferrer C, Fernández-Velado E, Rodríguez-Sánchez S, Mínguez A, Mancebo A, Barrio J, Lario S, de La Cruz DR, Hernández-Camba A, Rodríguez-Gutiérrez C, Chaparro M, Ricart E, Almenara-Michelena L, Balaguer A, Domènech E, Nos P

doi: 10.1002/ueg2.70223

Inflammatory Bowel Disease

Stricture dynamics and prognosis during biologic therapy in ileal Crohn's disease: a real-world cohort

Inflamm Bowel Dis

Takenaka K, Kawamoto A, Hibiya S, Tamura A, Morikawa R, Shimizu H, Fujii T, Ohtsuka K, Okamoto R

doi: 10.1093/ibd/izag012

Inflammatory Bowel Disease

Therapeutic Benefit of Upadacitinib in Severe Post-Proctectomy (Class 4) Perianal Crohn's Disease: A Three-Patient Case Series

Inflamm Bowel Dis

Hanna LN, Quraishi B, Pelly T, Lung P, Tozer P, Hart A, Wong SY, Powell N

doi: 10.1093/ibd/izaf216

Inflammatory Bowel Disease

Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study

J Crohns Colitis

Peyrin-Biroulet L, Atreya R, Danese S, Lindsay JO, Chapman JC, Anschutz T, Huang X, Zambrano J, van Haaren S, Joshi N, Duan WR, Cross RK

doi: 10.1093/ecco-jcc/jjaf213

Inflammatory Bowel Disease

Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial

J Crohns Colitis

Raine T, Danese S, Schreiber S, Gao X, Hanauer S, Torres J, Cunneen C, Kligys K, Huang X, Garrison A, Neimark E, Anschutz T, Crowley J, Cross RK

doi: 10.1093/ecco-jcc/jjag104

Gastroenterology

Clinical outcomes following switch from risankizumab to guselkumab in Crohn's disease: a real-world case series

Related content

Establishing a Multiple Outcome Set for Crohn's Disease in Real-World Evidence Studies: Results from a Delphi e-Survey

Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: the USBIOS IG-IBD Study

Clinical Outcome After Entero-Enteric Anastomosis for Crohn's Disease: A Case-Control Study

Real-World Effectiveness of Upadacitinib for Perianal Crohn's Disease: A Multi-Center Retrospective Study

Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry

Stricture dynamics and prognosis during biologic therapy in ileal Crohn's disease: a real-world cohort

Therapeutic Benefit of Upadacitinib in Severe Post-Proctectomy (Class 4) Perianal Crohn's Disease: A Three-Patient Case Series

Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study

Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial